MannKind Corp (MNKD) - Total Assets
Based on the latest financial reports, MannKind Corp (MNKD) holds total assets worth $744.40 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of MannKind Corp to assess how comfortably operating cash covers total debt obligations.
MannKind Corp - Total Assets Trend (2000–2025)
This chart illustrates how MannKind Corp's total assets have evolved over time, based on quarterly financial data. See net assets of MannKind Corp for net asset value and shareholders' equity analysis.
MannKind Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
MannKind Corp's total assets of $744.40 Million consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.5% |
| Accounts Receivable | $38.37 Million | 4.8% |
| Inventory | $35.31 Million | 4.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.07 Million | 0.6% |
| Goodwill | $67.59 Million | 8.5% |
Asset Composition Trend (2000–2025)
This chart illustrates how MannKind Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MNKD market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MannKind Corp's current assets represent 36.8% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2025, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 8.5% of total assets.
MannKind Corp Competitors by Total Assets
Key competitors of MannKind Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
MannKind Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.36 | 2.98 |
| Quick Ratio | 1.50 | 2.11 | 2.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $116.60 Million | $157.80 Million | $119.47 Million |
MannKind Corp - Advanced Valuation Insights
This section examines the relationship between MannKind Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 187.85 |
| Latest Market Cap to Assets Ratio | 1.46 |
| Asset Growth Rate (YoY) | 101.1% |
| Total Assets | $792.18 Million |
| Market Capitalization | $1.16 Billion USD |
Valuation Analysis
Above Book Valuation: The market values MannKind Corp's assets above their book value (1.46x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: MannKind Corp's assets grew by 101.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MannKind Corp (2000–2025)
The table below shows the annual total assets of MannKind Corp from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $792.18 Million | +101.14% |
| 2024-12-31 | $393.84 Million | -17.12% |
| 2023-12-31 | $475.20 Million | +60.93% |
| 2022-12-31 | $295.28 Million | -8.06% |
| 2021-12-31 | $321.16 Million | +195.71% |
| 2020-12-31 | $108.61 Million | +15.88% |
| 2019-12-31 | $93.72 Million | -12.98% |
| 2018-12-31 | $107.70 Million | +27.35% |
| 2017-12-31 | $84.58 Million | -21.00% |
| 2016-12-31 | $107.06 Million | -15.31% |
| 2015-12-31 | $126.41 Million | -67.95% |
| 2014-12-31 | $394.44 Million | +52.50% |
| 2013-12-31 | $258.65 Million | +2.92% |
| 2012-12-31 | $251.31 Million | +25.94% |
| 2011-12-31 | $199.55 Million | -28.03% |
| 2010-12-31 | $277.26 Million | +12.07% |
| 2009-12-31 | $247.40 Million | -12.41% |
| 2008-12-31 | $282.46 Million | -48.02% |
| 2007-12-31 | $543.44 Million | +0.69% |
| 2006-12-31 | $539.74 Million | +136.34% |
| 2005-12-31 | $228.37 Million | +39.69% |
| 2004-12-31 | $163.48 Million | +29.88% |
| 2003-12-31 | $125.88 Million | +20.14% |
| 2002-12-31 | $104.77 Million | +145.69% |
| 2000-12-31 | $42.65 Million | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more